A phase IIb trial of MLE-4901 in patients with vasomotor symptoms
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Pavinetant (Primary)
- Indications Hot flashes; Vasomotor symptoms
- Focus Therapeutic Use
- Sponsors Millendo Therapeutics
- 08 Nov 2017 Status changed from planning to discontinued, as reported in a Millendo Therapeutics media release.
- 08 Apr 2017 New trial record
- 03 Apr 2017 According to a Millendo Therapeutics media release, this trial is expected to initiate later in 2017.